Breaking News Instant updates and real-time market news.

GMXAY

Genmab ticker changed to GMAB

$0.00

(0.00%)

, JNJ

Johnson & Johnson

$138.09

0.86 (0.63%)

06:53
03/22/19
03/22
06:53
03/22/19
06:53

Genmab announces regulatory submission for daratumumab to EMA

Genmab (GMXAY) announced that Janssen (JNJ) has submitted a Type II variation application to the European Medicines Agency, or EMA. The application seeks to broaden the existing marketing authorization for daratumumab to include use in combination with lenalidomide and dexamethasone, or Rd, as treatment for newly diagnosed multiple myeloma patients who are not candidates for high dose chemotherapy and autologous stem cell transplant, or ASCT. The submission is based on data from the Phase III MAIA study of daratumumab in combination with Rd as treatment for patients with newly diagnosed multiple myeloma, who are not candidates for high dose chemotherapy and ASCT.

GMXAY

Genmab ticker changed to GMAB

$0.00

(0.00%)

JNJ

Johnson & Johnson

$138.09

0.86 (0.63%)

  • 16

    Apr

  • 25

    Apr

GMXAY Genmab ticker changed to GMAB
$0.00

(0.00%)

06/20/18
JPMS
06/20/18
UPGRADE
JPMS
Overweight
Genmab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Quigley upgraded Genmab with an increased price target of 1,150 kroner. The market is overly cautious on Darzalex competition and recent pullback in shares offers an attractive entry point, Quigley tells investors in a research note.
10/01/18
HCWC
10/01/18
INITIATION
HCWC
Buy
Genmab initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Genmab with a Buy rating and DKK 1,600 price target.
12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
Genmab upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Richard Parkes upgraded Genmab to Buy and raised his price target for the shares to DKK 1,250 from DKK 1,220. The analyst says the shares are "well underpinned" by Darzalex while the company's pipeline is maturing.
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Neutral
Genmab downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Vosser downgraded Genmab to Neutral with an unchanged price target of FKK 1,150. The analyst believes Darzalex's potential is largely reflected in the shares at current levels.
JNJ Johnson & Johnson
$138.09

0.86 (0.63%)

02/25/19
COWN
02/25/19
NO CHANGE
Target $155
COWN
Outperform
Johnson & Johnson 2019 targets appear achievable, says Cowen
Cowen analyst Joshua Jennings believes the top and bottom line targets for Johnson & Johnson are achievable while the "crown jewel" Pharma franchise is well positioned to reaccelerate in 2020 and beyond. He also believes the company's talc issues are manageable. Jennings reiterated his Outperform rating and $155 price target on Johnson & Johnson shares.
02/27/19
CHDN
02/27/19
NO CHANGE
Target $40
CHDN
Buy
MeiraGTx price target raised to $40 from $30 at Chardan
Chardan analyst Gbola Amusa raised his price target for MeiraGTx Holdings (MGTX) to $40 from $30 following Johnson & Johnson's equity stake in the company. MeiraGTx , a top pick for 2019 at Chardan, announced a strategic collaboration on inherited retinal diseases with J&J's Janssen Pharmaceuticals and an $80M private placement, with the investment arm of J&J taking a $40M stake, Amusa tells investors in a research note. The news represents the third announced collaboration or investment by a J&J vehicle in MeiraGTx, the analyst points out. This may signal potential takeover interest by J&J longer term and suggests the pharma giant sees significant value in the inherited retinal diseases market opportunities, contends Amusa. He keeps a Buy rating on MeiraGTx.
03/15/19
BARD
03/15/19
NO CHANGE
BARD
Stryker, Wright Medical best positioned in medical robotics, says Baird
Following meetings at American Academy of Orthopaedic Surgeons this week, Baird analyst Jeff Johnson said that Stryker (SYK) remained the "clear robotics leader," and added that Smith & Nephew (SNN), Zimmer Biomet (ZBH), and to a lesser extent Johnson & Johnson (JNJ) were all "making progress." The analyst came away most positive on Stryker, due to momentum in multiple pipelines, and Wright Medical (WMGI), due to its core business strength and its intriguing pipeline. Johnson has an Outperform rating and $201 price target on Stryker, and Outperform rating and $36 price target on Wright Medical Group.
03/15/19
FBCO
03/15/19
NO CHANGE
FBCO
Outperform
J&J talc risk more than accounted for in current valuation, says Credit Suisse
Credit Suisse analyst Vamil Divan said a $29M jury award to a woman who claimed that asbestos in baby powder led to her development of mesothelioma has brought potential litigation risk for Johnson & Johnson back into the headlines. However, he spoke to Johnson & Johnson and they remain confident in the safety of their product, stating that they plan to appeal and feel there were serious procedural and evidentiary errors made in the trial. Divan, who believes the potential risk from talc cases has been "more than sufficiently accounted for" in the current valuation of J&J shares, also thinks that multiple ongoing cases will hopefully lead to more clarity soon. He keeps an Outperform rating on Johnson & Johnson shares.

TODAY'S FREE FLY STORIES

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary  »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$38.33

-0.36 (-0.93%)

18:29
09/17/19
09/17
18:29
09/17/19
18:29
Hot Stocks
FB Financial acquires FNB Financial »

FB Financial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

GM

General Motors

$38.28

1.07 (2.88%)

18:28
09/17/19
09/17
18:28
09/17/19
18:28
Periodicals
GM stops paying health insurance costs for union workers on strike, Reuters says »

General Motors has moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$52.85

0.08 (0.15%)

18:25
09/17/19
09/17
18:25
09/17/19
18:25
Periodicals
Total CEO says Saudi oil facility strikes will have consequences, Reuters says »

Total CEO Patrick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SMMF

Summit Financial Group

$25.96

-0.29 (-1.10%)

18:02
09/17/19
09/17
18:02
09/17/19
18:02
Hot Stocks
Summit Financial and Cornerstone Financial sign merger agreement »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$30.93

-0.89 (-2.80%)

18:01
09/17/19
09/17
18:01
09/17/19
18:01
Earnings
Steel Dynamics sees Q3 EPS 66c-70c, consensus 71c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

18:00
09/17/19
09/17
18:00
09/17/19
18:00
Hot Stocks
Breaking Hot Stocks news story on FedEx »

FedEx says FY21 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:59
09/17/19
09/17
17:59
09/17/19
17:59
Hot Stocks
FedEx says new FY20 EPS forecast assumes no further weakening in economic growth »

Says FY20 ground…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

BTI

British American Tobacco

$36.84

0.825 (2.29%)

, PM

Philip Morris

$71.98

-0.54 (-0.74%)

17:57
09/17/19
09/17
17:57
09/17/19
17:57
General News
NY State implements first-in-nation ban on flavored e-cigarettes »

Governor Andrew M. Cuomo…

BTI

British American Tobacco

$36.84

0.825 (2.29%)

PM

Philip Morris

$71.98

-0.54 (-0.74%)

MO

Altria Group

$41.31

-0.1 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MRK

Merck

$82.53

0.52 (0.63%)

17:57
09/17/19
09/17
17:57
09/17/19
17:57
Hot Stocks
Merck says FDA approves Keytruda-Lenvima combo treatment »

Merck and Eisai announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

ENB

Enbridge

$35.27

0.1 (0.28%)

17:56
09/17/19
09/17
17:56
09/17/19
17:56
Hot Stocks
Enbridge says Minnesota Supreme Court rejects L3RP FEIS appeals »

Enbridge said it supports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:47
09/17/19
09/17
17:47
09/17/19
17:47
Hot Stocks
FedEx EVP Carere says building 'powerful relationships' with many retailers »

Says forged new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.